The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Urinary tract infections in patients with diabetes treated with dapagliflozin
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Self-citationMeng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.250 · Cited by 396 · cited 1×
“It has been established that treatment with dapagliflozin produces glucosuria with a reduction in blood glucose levels (Ferrannini, Ramos, Salsali, Tang, & List, 2010; Komoroski et al., 2009; List, Woo, Morales, Tang, & Fiedorek, 2009).”
Background
Cited by
Scheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Nauck, M. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s50773 · Cited by 343
Rosenstock, J., Hansen, L., Zee, P., Li, Y., Cook, W., Hirshberg, B., & Iqbal, N. (2015) · Diabetes Care · doi:10.2337/dc14-1142 · Cited by 290
Cefalu, W. T., Leiter, L. A., de Bruin, T. W. A., Gause-Nilsson, I., Sugg, J., & Parikh, S. J. (2015) · Diabetes Care · doi:10.2337/dc14-0315 · Cited by 182
Self-citationSchneeberger, C., Kazemier, B. M., & Geerlings, S. E. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000028 · Cited by 73
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1100167 · Cited by 70
“2 Dapagliflozin Safety data from 12 placebo-controlled RCTs with dapagliflozin were pooled to evaluate the relationship between glucosuria and UTI in patients with inadequately controlled diabetes.[85] There was no definitive dose relationship between glucosuria and UTIs.”
BackgroundCardiometabolic effects of a new class of antidiabetic agents
Desouza, C. V., Gupta, N., & Patel, A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.016 · Cited by 54
on behalf of the Scottish Diabetes Research Network Epidemiology Group, McGurnaghan, S. J., Brierley, L., Caparrotta, T. M., McKeigue, P. M., Blackbourn, L. A. K., Wild, S. H., Leese, G. P., McCrimmon, R. J., McKnight, J. A., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4806-9 · Cited by 46
Wang, C., Zhou, Y., Kong, Z., Wang, X., Lv, W., Geng, Z., & Wang, Y. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13620 · Cited by 39
Advances in Oral Anti‐Diabetes Drugs in Pregnancy
Mukerji, G., & Feig, D. S. (2017) · A Practical Manual of Diabetes in Pregnancy · doi:10.1002/9781119043805.ch15 · Cited by 2
Metadata
- Authors
- Johnsson, K. M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S. J., & List, J. F.
- Venue
- Journal of Diabetes and its Complications
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 27
- Issue
- 5
- Pages
- 473-478
- ISSN
- 0891-6632 (ISSN-L)
- 1056-8727
- OpenAlex
- W2162427196
- Cited by
- 205
- References
- 3
- FWCI
- 19.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.